<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864938</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/1949/2020</org_study_id>
    <nct_id>NCT04864938</nct_id>
  </id_info>
  <brief_title>Recovery After Critical Covid-19 Infection</brief_title>
  <acronym>RECOVID</acronym>
  <official_title>Recovery After Critical Covid-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Helsinki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study focuses on the recovery of respiratory, cardiovascular and&#xD;
      neurological/neuropsychological recovery after intensive care treatment for covid-19. The&#xD;
      results will be compared with those obtained from patients treated in the regular wards for&#xD;
      covid-19, persons with home treated covid-19 and non-covid controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients who have been treated in the intensive care units of Helsinki University&#xD;
      Hospital are invited to participate. Controls are recruited from follow-up clinics, and with&#xD;
      announcements in media and websites.&#xD;
&#xD;
      The participants receive an invitation to a follow-up clinic where their experiences from the&#xD;
      ICU treatment and recovery will be discussed. The investigators will perform neuropsychologic&#xD;
      testing (6 months post-discharge), a telephone interview (3 months) and send written&#xD;
      questionnaires (3, 6 and 24 months) to the participants. The participants will undergo MRI&#xD;
      imaging of the brain and laboratory tests will be taken. The olfactory function will be&#xD;
      tested at a follow-up clinic. Data on the patients´ respiratory function from clinical&#xD;
      spirometry and diffusion capacity testing 3 and 6 months after discharge are collected. The&#xD;
      patients will perform a 6 min walk test.&#xD;
&#xD;
      Data on coagulation laboratory values will be registered from acute phase and 6 months after&#xD;
      discharge. The investigators will also analyse ApoE alleles, neurofilament light and&#xD;
      NAD-metabolites and study their correlation with neuropsychologic findings and long term&#xD;
      symptoms (up to 5 years after hospital discharge).&#xD;
&#xD;
      Participants will also undergo magnetic resonance imaging of the heart at 6-12 months after&#xD;
      the hospital discharge, and laboratory samples, a symptom questionnaire and electrocardiogram&#xD;
      are collected. Inflammatory parameters and variables associated with regulating inflammation&#xD;
      and coagulation will be analysed.&#xD;
&#xD;
      Clinical data from the acute and post-acute phase and demographic data are collected from the&#xD;
      patient data management systems.&#xD;
&#xD;
      The target patient number is 75 intensive care treated patients and 50 control persons in&#xD;
      each three control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">July 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function 6 months after hospital discharge</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Global score calculated from three domains: memory, executive functions and attention.Memory: WMS-III Word list delayed recall + WMS-III Logical memory delayed recall + Rey Complex Figure, delayed recall Executive: TMB (time, reversed) + Stroop interference (time, reversed) + FAB score Attention: WAIS-IV Coding + CPT (correct items) + Stroop naming (time, reversed) The global score will be compared with controls and age matched national references</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffusion capacity 6 months after hospital discharge</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Diffusion capacity DLCO results (percentage of predicted) 6 months after ICU treatment for covid-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of post myocarditis findings in MRI of the heart</measure>
    <time_frame>6-12 months after hospital discharge</time_frame>
    <description>Incidence of findings in cardiac MRI indicating previous myocarditis in each group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Six minute walk test distance</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>The distance in meters walked by ICU treated patients in 6 minutes in controlled test environment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Restriction in lung function tests</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Restriction in lung function parameters vital capacity and forced vital capacity (z-scores) in measured by spirometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral microbleeds</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Number and anatomical distribution of cerebral microbleeds in MRI imaging of the brain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma matrix metalloproteinases -8, -9 and TIMP-1 6 months after hospital discharge</measure>
    <time_frame>6 moths after hospital discharge</time_frame>
    <description>Plasma matrix metalloproteinases -8, -9 and TIMP-1 levels in ng/mL 6 months after hospital discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma neurofilament level and its correlation with global score in neuropsychological test battery</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Plasma neurofilament level and its correlation with global score in neuropsychological test battery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation ApoE 4 alleles with disease severity</measure>
    <time_frame>6 months post-covid</time_frame>
    <description>Laboratory analysis of ApoE alleles and comparison of their frequencies among groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of cerebral microbleeds with neuropsychological global score</measure>
    <time_frame>6 moths after hospital discharge</time_frame>
    <description>Correlation of type and location of cerebral microbleeds with neuropsychological global score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of the incidence of cerebral microbleeds with findings in cardiac MRI</measure>
    <time_frame>6-12 months after hospital discharge</time_frame>
    <description>Association of the incidence of cerebral microbleeds with findings in cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of plasma neurofilament with cerebral microbleeds</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Correlation of plasma neurofilament with cerebral microbleeds in brain MR imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of 6 minute walk test heart rate variables with cardiac function</measure>
    <time_frame>6-12 months after hospital discharge</time_frame>
    <description>Correlation of heart rate in rest, exercise and 5 minutes after exercise with cardiac output measured in heart MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of matrix metalloproteinase 9 with diffusion capacity</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Correlation of matrix metalloproteinase 9 (ng/mL) with lung diffusion capacity z-score</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Patients: ICU treated covid-19 patients</arm_group_label>
    <description>Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 1, covid-19 patients treated in the regular wards</arm_group_label>
    <description>As above, without 6 minute walk test or routine chest x-ray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 2, persons with covid-19 without hospitalization</arm_group_label>
    <description>As above, but without respiratory testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 3, non-covid controls</arm_group_label>
    <description>As control group 2</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      After separate informed consent whole blood specimens have been collected for ApoE allele&#xD;
      analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are recovering from critical covid-infection and controls that are either&#xD;
        patients recovering from a hospital regular ward treated for covid or covid that has not&#xD;
        required hospitalisation. Non-covid controls are age and sex-matched persons (matched to&#xD;
        ICU treated group of participants) with no covid-19 in history.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-100&#xD;
&#xD;
          -  Positive PCR for Sars-CoV-2 (except non-covid controls, who must be negative)&#xD;
&#xD;
          -  Native language Finnish or Swedish&#xD;
&#xD;
          -  Informed consent to study to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Major neurologic diagnosis (TBI, dementia, stroke, Parkinson´s disease before&#xD;
             covid-19)&#xD;
&#xD;
          -  Substantially impaired hearing or vision&#xD;
&#xD;
          -  Developmental disability.&#xD;
&#xD;
          -  No consent to study participation&#xD;
&#xD;
          -  Contraindication to MR imaging (such as cardiac pacemaker, allergy to contrast)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>Capital Province Of Finland</state>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Helsinki</investigator_affiliation>
    <investigator_full_name>Johanna Hastbacka</investigator_full_name>
    <investigator_title>Adjunct professor</investigator_title>
  </responsible_party>
  <keyword>intensive care unit</keyword>
  <keyword>cognitive function</keyword>
  <keyword>delirium</keyword>
  <keyword>post-traumatic stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

